Likmez Shortage: What Providers and Prescribers Need to Know in 2026

Likmez (metronidazole oral suspension 500 mg/5 mL) addresses a genuine clinical gap: the first and only FDA-approved ready-to-use liquid metronidazole formulation in the US. For prescribers who manage patients with dysphagia, adherence barriers, or pediatric antibiotic needs, this drug is a meaningful advance. However, pharmacy access remains inconsistent as of 2026. This guide provides a clinical overview to help you navigate prescribing, patient access, and appropriate alternatives.

Likmez: Clinical Overview for Prescribers

Likmez was FDA-approved September 25, 2023 under NDA 505(b)(2) by Saptalis Pharmaceuticals. It is a ready-to-use suspension at 500 mg metronidazole per 5 mL, with no refrigeration required, strawberry-peppermint flavoring, and shelf stability at room temperature.

FDA-Approved Indications:

• Trichomoniasis (Trichomonas vaginalis) in adult females and males — symptomatic and asymptomatic
• Amebiasis (acute intestinal amebiasis and amebic liver abscess) in adults and pediatric patients
• Anaerobic bacterial infections in adults (intra-abdominal, skin/skin structure, gynecologic, CNS, lower respiratory, endocarditis, bone/joint infections)

Key dosing reminders:

• Trichomoniasis: 2g (20 mL) as a single dose, or 250 mg (2.5 mL) TID x 7 days. Treat sexual partners concurrently.
• Amebiasis (adults): 750 mg (7.5 mL) TID x 5-10 days. Pediatric: 35-50 mg/kg/24h divided TID x 10 days, max 2250 mg/24h.
• Anaerobic infections (adults): 7.5 mg/kg q6h (~500 mg/5 mL for 70 kg patient), max 4 g (40 mL)/24h, 7-10 days (may require longer for bone/joint, lower respiratory, endocardium).
• Hepatic impairment: Reduce dose by 50% in severe hepatic impairment. No renal adjustment for CAPD; consider supplemental dose after hemodialysis.

Current Availability Status

As of 2026, there is no FDA or ASHP-declared shortage of Likmez. However, clinicians consistently report that retail pharmacies often do not stock it due to low ordering frequency relative to generic metronidazole tablets. This is a distribution and formulary issue, not a manufacturing shortage.

Prescribers should counsel patients to call ahead or request medfinder assistance before assuming the prescription can't be filled. Most major drug wholesalers (McKesson, AmerisourceBergen, Cardinal Health) carry Likmez, so pharmacies can often order it within 1-2 business days if they don't stock it.

When to Prescribe Likmez vs. Generic Metronidazole Tablets

Given the significantly higher cost of Likmez ($200+ vs. $5-10 for generic tablets), it should be reserved for patients with a clear clinical need for the liquid formulation. Consider Likmez specifically for:

• Patients with dysphagia or swallowing disorders (neurological, post-stroke, post-surgical, esophageal conditions)
• Pediatric patients requiring amebiasis treatment (Likmez is FDA-approved for pediatric amebiasis)
• Patients with documented adherence failure due to inability to swallow tablets or taste aversion
• Patients where off-label compounded liquid metronidazole was previously being used (providing an FDA-approved alternative)

Evidence-Based Alternatives When Likmez Is Unavailable

For trichomoniasis: Tinidazole 2g as a single oral dose (CDC-recommended alternative). Fewer doses required; may have slightly better GI tolerability. Only available as tablets.

For amebiasis: Tinidazole 2g daily x 3 days (intestinal) or x 5 days (liver abscess) is an effective alternative for patients who can take tablets. Paromomycin is an option for luminal amebiasis.

For anaerobic bacterial infections: Clindamycin (oral or IV) provides good anaerobic coverage and is available in liquid form (solution, 75 mg/5 mL). Beta-lactam/beta-lactamase inhibitor combinations (amoxicillin-clavulanate, piperacillin-tazobactam) also provide anaerobic coverage depending on organisms and clinical context.

Insurance and Prior Authorization Considerations

Many payers require prior authorization for Likmez, citing the availability of less expensive generic metronidazole tablets. To support a PA request, document:

• Clinical indication (diagnosis with ICD-10 code)
• Reason liquid formulation is medically necessary (dysphagia diagnosis, swallowing evaluation results, documented inability to use tablets)
• Prior failure or contraindication to generic metronidazole tablets if applicable

Key Contraindications and Safety Reminders

The BOXED WARNING for Likmez states that metronidazole has been shown to be carcinogenic in mice and rats — avoid unnecessary use. Reserve for confirmed or strongly suspected bacterial or parasitic infections.

Absolute contraindications: Hypersensitivity to metronidazole or nitroimidazoles; disulfiram use within 2 weeks; alcohol or propylene glycol use during therapy and 3 days after; Cockayne syndrome (risk of severe irreversible hepatotoxicity).

Key interactions: Warfarin (increased INR — consider more frequent INR monitoring); lithium (elevated levels); phenytoin (increased levels); lopinavir/ritonavir oral solution (contains propylene glycol — contraindicated combination).

How Providers Can Help Patients Find Likmez

When prescribing Likmez, proactively counsel patients that not all pharmacies carry it and they may need to call around. You can also direct them to medfinder for Providers — a service that calls pharmacies near your patients to check stock, saving them time and reducing the chance of prescription abandonment.

See our full guide: How to Help Your Patients Find Likmez in Stock: A Provider's Guide.